Business
Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130
Dosing In Human Clinical Trial To Commence Within Weeks Vancouver, British Columbia--(Newsfile C...
About this update from Lobe Sciences Ltd
[{"type":"text","content":"Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130Dosing In Human Clinical Trial To Commence Within WeeksVancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (\"Lobe\" or the \"Company\"), a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that its exclusive commercial manufacturing partner has received their initial 2023 quota for our novel psilocin drug product (L-130) from the Drug Enforcement Administration (DEA). Mr. Philip J. Young, Chairman and Chief Executive Officer of the Company stated, \"This is the final step of the DEA process which is required for the commercial production of Schedule 1 compounds for export for the conduct of human clinical trials. Our commercial packaging partner partnered with Quality Chemical Laboratories (\"QCL\") received this quota which can be increased as our programs mature and advance. We are now in position to initiate two clinical studies within the next several months. The first will be our Ph. 1 study of L-130 to evaluate its safety and Pharmacokinetics profile in healthy volunteers. The second study will be conducted under the leadership of Dr. Lauren Natbony and will evaluate the safety of L-130 in patients with Chronic Cluster Headaches (\"CCH\"). The team was able to take advantage of the delay in initiating the Ph 1 safety study and have been able to draft all the necessary documentation to support the conduct of both studies and open dialogue with the Food and Drug Association (\"FDA\") leading to the filing of an Investigational New Drug Application (\"IND\") and preparing for a Phase 2 clinical trial in Australia.\"Mr. Maghsoud Dariani, Chief Science Officer of the Company added, \"We are pleased that through diligent and effective communications with the DEA, we were able to submit the supportive data which led to approval of the initial quota for our L-130 drug product so that we can begin our clinical trials towards developing novel treatments for Orphan and rare diseases with unmet needs.\"About Lobe Sciences Ltd.Lobe Sciences is a biopharmaceutical company focused on developing patient-friendly, easily administered medicines for orphan ...